A joint project of the Graduate School, Peabody College, and the Jean & Alexander Heard Library

Title page for ETD etd-11252013-155559


Type of Document Master's Thesis
Author Shah, Amy Trushar
Author's Email Address a.shah@vanderbilt.edu
URN etd-11252013-155559
Title Autofluorescence Imaging Reflects Metabolic Response to Treatment in Human Head and Neck Squamous Cell Carcinoma
Degree Master of Science
Department Biomedical Engineering
Advisory Committee
Advisor Name Title
H. Charles Manning Committee Member
Melissa Skala Committee Member
Keywords
  • autofluorescence
  • metabolism
  • head and neck cancer
Date of Defense 2013-12-02
Availability unrestricted
Abstract
Optical metabolic imaging measures fluorescence intensity and lifetimes from metabolic cofactors nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FAD). These molecular level measurements provide unique biomarkers for early cellular responses to cancer treatments. Head and neck squamous cell carcinoma (HNSCC) is an attractive target for optical imaging because of easy access to the site using fiber optic probes. Two HNSCC cell lines, SCC25 and SCC61, were treated with Cetuximab (anti-EGFR antibody), BGT226 (PI3K/mTOR inhibitor), or cisplatin (chemotherapy) for 24 hours. Results show increased redox ratio, NADH α1 (contribution from free NADH), and FAD α1 (contribution from protein-bound FAD) for malignant cells compared with the nonmalignant cell line OKF6 (p<0.05). In SCC25 and SCC61 cells, the redox ratio is unaffected by cetuximab treatment and decreases with BGT226 and cisplatin treatment (p<0.05), and these results agree with standard measurements of proliferation rates after treatment. For SCC25, NADH α1 is reduced with BGT226 and cisplatin treatment. For SCC61, NADH α1 is reduced with cetuximab, BGT226, and cisplatin treatment. Trends in NADH α1 are statistically similar to changes in standard measurements of glycolytic rates after treatment. FAD α1 is reduced with cisplatin treatment (p<0.05). These shifts in optical endpoints reflect early metabolic changes induced by drug treatment. Overall, these results indicate that optical metabolic imaging has potential to detect early response to cancer treatment in HNSCC, enabling optimal treatment regimens and improved patient outcomes.
Files
  Filename       Size       Approximate Download Time (Hours:Minutes:Seconds) 
 
 28.8 Modem   56K Modem   ISDN (64 Kb)   ISDN (128 Kb)   Higher-speed Access 
  MS_thesis_Shah.pdf 1.49 Mb 00:06:54 00:03:33 00:03:06 00:01:33 00:00:07

Browse All Available ETDs by ( Author | Department )

If you have more questions or technical problems, please Contact LITS.